KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin (2016 - 2025)

Pacira BioSciences has reported Gross Margin over the past 16 years, most recently at 79.53% for Q4 2025.

  • Quarterly results put Gross Margin at 79.53% for Q4 2025, up 83.0% from a year ago — trailing twelve months through Dec 2025 was 79.39% (up 370.0% YoY), and the annual figure for FY2025 was 79.39%, up 370.0%.
  • Gross Margin for Q4 2025 was 79.53% at Pacira BioSciences, down from 80.91% in the prior quarter.
  • Over the last five years, Gross Margin for PCRX hit a ceiling of 112.58% in Q4 2022 and a floor of 69.43% in Q1 2023.
  • Median Gross Margin over the past 5 years was 75.32% (2021), compared with a mean of 76.8%.
  • Biggest five-year swings in Gross Margin: skyrocketed 3708bps in 2022 and later plummeted -3889bps in 2023.
  • Pacira BioSciences' Gross Margin stood at 75.5% in 2021, then skyrocketed by 49bps to 112.58% in 2022, then plummeted by -35bps to 73.69% in 2023, then grew by 7bps to 78.7% in 2024, then increased by 1bps to 79.53% in 2025.
  • The last three reported values for Gross Margin were 79.53% (Q4 2025), 80.91% (Q3 2025), and 77.43% (Q2 2025) per Business Quant data.